Literature DB >> 7777060

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.

J Lukas1, D Parry, L Aagaard, D J Mann, J Bartkova, M Strauss, G Peters, J Bartek.   

Abstract

D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777060     DOI: 10.1038/375503a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  228 in total

1.  Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway.

Authors:  E Santoni-Rugiu; J Falck; N Mailand; J Bartek; J Lukas
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 2.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Establishment of irreversible growth arrest in myogenic differentiation requires the RB LXCXE-binding function.

Authors:  T T Chen; J Y Wang
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 4.  Epigenetic changes accompanying human mammary epithelial cell immortalization.

Authors:  P Yaswen; M R Stampfer
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-04       Impact factor: 2.673

5.  Loss of p19(ARF) eliminates the requirement for the pRB-binding motif in simian virus 40 large T antigen-mediated transformation.

Authors:  H H Chao; A M Buchmann; J A DeCaprio
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

6.  Opposing roles of pRB and p107 in adipocyte differentiation.

Authors:  M Classon; B K Kennedy; R Mulloy; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

7.  Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control.

Authors:  M Classon; S Salama; C Gorka; R Mulloy; P Braun; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

8.  Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3.

Authors:  B Mannhardt; S A Weinzimer; M Wagner; M Fiedler; P Cohen; P Jansen-Dürr; W Zwerschke
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

9.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

10.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.